B · Normal
[Fosun Pharma: Its controlled subsidiary drug HLX105 has been approved for clinical trials] On November 16, Fosun Pharmaceutical (600196.SH) announced that the company's controlled subsidiary Henlius received approval from the National Medical Products Administration to conduct a Phase I clinical trial of HLX105 for injection for the treatment of advanced/metastatic solid tumors. HLX105 is an antibody fusion protein independently developed by the company that combines a PD-1 antibody with an IL-2 variant. As of October 2026, the cumulative R&D investment has been approximately RMB 40 million.
Comments